Peregrine Pharmaceuticals says bavituximab prompts response in breast cancer patientsPeregrine drug prompts response in cancer study TUSTIN, Calif. — Peregrine Pharmaceuticals Inc. said Wednesday its drug candidate bavituximab prompted an improvement in response rates in advanced breast cancer patients during a midstage clinical trial. |